Articles by Hellen Berger - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Hellen Berger

Hellen Berger


Hellen Berger is a business writer based in Sao Paulo, Brazil.

Articles
Brazil's Phytotherapic Drug Market and Regulation
July 2, 2014

Is there potential for growth in Brazil's phytotherapic drug market?

Global Instability Impacts Brazil's Pharma Market
May 2, 2014

How badly is Brazil's pharmaceutical market suffering from the global instability of emerging markets?

Global Instability Affects the Pharma Market in Brazil
April 2, 2014

How badly is Brazil's pharmaceutical market suffering from the global instability of emerging markets?

Innovation and Market Growth in Brazil
January 2, 2014

Brazil is the first Latin American country to emerge as a global biopharmaceutical collaborator.

Report from Brazil
November 2, 2013

New regulation offers patients in Brazil greater access to experimental drugs.

Report from Brazil
September 2, 2013

Pharma eyes biologics production in Brazil as the government begins to recognize the potential of these drugs.

Report from Brazil
July 2, 2013

Brazil offers opportunities and challenges for global pharmaceutical companies.

Report from Brazil
May 2, 2013

Prior to price escalation of pharmaceutical products in Brazil, the country's regulatory authority released a study on price-cap control and its benefits in the past years.

Report from Brazil
March 2, 2013

Brazil's major vaccine producer innovates with stem-cell research.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
FindPharma Custom Search
Click here